CytotoxicityNCT07381153
In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs
An observational study of Cytotoxicity, run by Cairo University at 1 site in Egypt.
Trial summary
This study aims to evaluate the cytotoxicity of INOX (Nanoksa G Plus) high-performance polymer discs on cell cultures using standardized in-vitro assays. The primary objective is to assess cell viability after exposure to INOX extracts. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Cytotoxicity
- How many people
- 20 participants
- Where
- 1 siteEgypt
- Study dates
- 20 Jan 2027to 30 Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Invitro study to evaluate the cytotoxicity of INOX (Nanoksa G Plus) high-performance polymer discs on cell cultures using standardized in-vitro assays.
Who may be able to join
- To assess cell viability following exposure to INOX material extracts using a quantitative cell viability assay.
Who cannot join
- To evaluate cell membrane integrity following exposure to INOX extracts. To assess cellular morphology after exposure to the material. To compare cytotoxic effects at different extract concentrations. To determine whether INOX meets accepted non-cytotoxicity thresholds.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Cytotoxicity Evaluation of INOX (Nanoksa G Plus) High-Performance Polymer Discs on Cell Cultures: An In-Vitro Experimental Study
This study aims to evaluate the cytotoxicity of INOX (Nanoksa G Plus) high-performance polymer discs on cell cultures using standardized in-vitro assays. The primary objective is to assess cell viability after exposure to INOX extracts. Secondary objectives include examining cell membrane integrity, cellular morphology, comparing effects across extract concentrations, and determining whether INOX meets accepted non-cytotoxicity standards.
- Conditions
- Cytotoxicity
- Keywords
- INOX, Nanoksa G Plus, INVITRO
What is being measured
The primary outcome is the main question the study is designed to answer.
Cell viability
Cell viability, assessed using a quantitative assay (MTT, XTT, or Alamar Blue).
Measured: JANUARY 2026
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Feb 2026
- Study start20 Jan 2027 (estimated)
- Primary completion25 Jan 2027 (estimated)
- Study completion30 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CytotoxicityStudies of the same condition, open and under way.
- More trials run by Cairo UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Cairo University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ghada Adayil, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07381153
- Sponsor's protocol ID
- 12l2025
- Status last verified
- Jan 2026
- First submitted
- 24 Jan 2026
- Last updated
- 19 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cytotoxicity Evaluation of INOX (Nanoksa G Plus) High-Performance Polymer Discs on Cell Cultures: An In-Vitro Experimental Study
- ClinicalTrials.gov ID
- NCT07381153
- Acronym / sponsor ID
- 12l2025
- Conditions
- Cytotoxicity
- Keywords
- INOX, Nanoksa G Plus, INVITRO
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Cairo UniversityUniversity, hospital or other
- Study start
- 20 Jan 2027 (estimated)
- Primary completion
- 25 Jan 2027 (estimated)
- Study completion
- 30 Jan 2027 (estimated)
- First posted
- 2 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the cytotoxicity of INOX (Nanoksa G Plus) high-performance polymer discs on cell cultures using standardized in-vitro assays. The primary objective is to assess cell viability after exposure to INOX extracts. Secondary objectives include examining cell membrane integrity, cellular morphology, comparing effects across extract concentrations, and determining whether INOX meets accepted non-cytotoxicity standards.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Invitro study to evaluate the cytotoxicity of INOX (Nanoksa G Plus) high-performance polymer discs on cell cultures using standardized in-vitro assays.
Key inclusion criteria (1 listed)
- To assess cell viability following exposure to INOX material extracts using a quantitative cell viability assay.
Key exclusion criteria (1 listed)
- To evaluate cell membrane integrity following exposure to INOX extracts. To assess cellular morphology after exposure to the material. To compare cytotoxic effects at different extract concentrations. To determine whether INOX meets accepted non-cytotoxicity thresholds.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cell viability
Time frame: JANUARY 2026
Cell viability, assessed using a quantitative assay (MTT, XTT, or Alamar Blue).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2026.
Related trials for Cytotoxicity
Not yet recruitingPhase 2/3
Anticariogenic Effect of Moringa Oleifera Mouthwash Compared to Chlorhexidine Mouthwash
Plaque, Dental, Antimicrobial
Not yet recruitingObservational study
Biological Evaluation of Orthopedic Materials: An In Vitro Study Using Patient-Derived Human Samples
Cytotoxicity
Not yet recruitingObservational study
Effects of Chlorhexidine on Human Gingival Fibroblasts
HGF, Fibroblast
Not yet recruiting
Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies
Solid Tumor, Adult, Cytotoxicity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cytotoxicity, run by Cairo University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cell viability (time frame: JANUARY 2026). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026; AzTrials last refreshed its copy on 8 Nov 2026.